We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Aclaris Therapeutics
ACRS
$858M
| $226K | ﹤0.01% |
14,336
+3,174
| +28% | +$51.1K |
|
2052
Middleby
MIDD
$5.69B
| $226K | ﹤0.01% |
1,686
-547
| -24% | -$74.5K |
|
2053
BlackLine
BL
$1.69B
| $225K | ﹤0.01% |
3,344
-2,593
| -44% | -$161K |
|
|
CDMO
2054
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $223K | ﹤0.01% |
16,210
-3,741
| -19% | -$57.3K |
|
2055
Boyd Gaming
BYD
$6.06B
| $223K | ﹤0.01% |
+4,137
| New | +$233K |
|
2056
DHT Holdings
DHT
$2.9B
| $220K | ﹤0.01% |
24,740
+7,014
| +40% | +$63.8K |
|
2057
Rush Street Interactive
RSI
$2.93B
| $219K | ﹤0.01% |
61,114
+42,813
| +234% | +$159K |
|
2058
Glacier Bancorp
GBCI
$6.35B
| $219K | ﹤0.01% |
+4,434
| New | +$239K |
|
2059
Zurn Elkay Water Solutions
ZWS
$8.62B
| $218K | ﹤0.01% |
10,330
-55,221
| -84% | -$1.3M |
|
2060
Alico
ALCO
$312M
| $218K | ﹤0.01% |
9,116
-11,993
| -57% | -$347K |
|
|
CTIC
2061
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $217K | ﹤0.01% |
36,153
+13,154
| +57% | +$71.8K |
|
2062
Viridian Therapeutics
VRDN
$2.63B
| $216K | ﹤0.01% |
+7,403
| New | +$171K |
|
2063
PagerDuty
PD
$925M
| $216K | ﹤0.01% |
+8,204
| New | +$194K |
|
2064
Gibraltar Industries
ROCK
$1.48B
| $215K | ﹤0.01% |
4,688
-2,216
| -32% | -$106K |
|
2065
York Water
YORW
$526M
| $214K | ﹤0.01% |
4,749
-7,580
| -61% | -$329K |
|
2066
Greene County Bancorp
GCBC
$584M
| $211K | ﹤0.01% |
7,348
+152
| +2% | +$5.07K |
|
2067
Kura Sushi USA
KRUS
$589M
| $210K | ﹤0.01% |
4,411
+1
| +0% | +$66 |
|
2068
Stanley Black & Decker
SWK
$15.7B
| $210K | ﹤0.01% |
2,801
+52
| +2% | +$4.06K |
|
|
HA
2069
DELISTED
Hawaiian Holdings, Inc.
HA
| $210K | ﹤0.01% |
+20,441
| New | +$273K |
|
2070
Karyopharm Therapeutics
KPTI
$44.6M
| $210K | ﹤0.01% |
4,110
-3,402
| -45% | -$236K |
|
2071
Elastic
ESTC
$7.98B
| $209K | ﹤0.01% |
4,137
-309
| -7% | -$18.5K |
|
2072
Wheels Up
UP
$189M
| $208K | ﹤0.01% |
1,011
-1,220
| -55% | -$315K |
|
2073
Geron
GERN
$1B
| $208K | ﹤0.01% |
85,800
+27,133
| +46% | +$60.8K |
|
2074
Outdoor Holding Co
POWW
$286M
| $208K | ﹤0.01% |
+120,002
| New | +$303K |
|
2075
Adtran
ADTN
$629M
| $205K | ﹤0.01% |
10,932
-884
| -7% | -$17.8K |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.